IP Library Assignment 075737/0001
Patent Assignment
Reel/Frame 075737/0001

Release of Security Interest

Recorded: 2026-06-12 Pages: 89
Assignor
COCOON SA LLC
Executed: 2026-06-11
Assignees
APCINTEX LIMITED
1 FEDERAL STREET, 38TH FLOOR, BOSTON, MASSACHUSETTS, 02110
JANPIX LIMITED
1 FEDERAL STREET, 38TH FLOOR, BOSTON, MASSACHUSETTS, 02110
CAPELLA BIOSCIENCE LTD
1 FEDERAL STREET, 38TH FLOOR, BOSTON, MASSACHUSETTS, 02110
LOCKBODY THERAPEUTICS LTD
1 FEDERAL STREET, 38TH FLOOR, BOSTON, MASSACHUSETTS, 02110
ULTRAHUMAN TWO LIMITED
1 FEDERAL STREET, 38TH FLOOR, BOSTON, MASSACHUSETTS, 02110
ULTRAHUMAN FOUR LIMITED
1 FEDERAL STREET, 38TH FLOOR, BOSTON, MASSACHUSETTS, 02110
MORPHOGEN-IX LIMITED
1 FEDERAL STREET, 38TH FLOOR, BOSTON, MASSACHUSETTS, 02110
OREXIA THERAPEUTICS LIMITED
1 FEDERAL STREET, 38TH FLOOR, BOSTON, MASSACHUSETTS, 02110
CARDIOKINE BIOPHARMA LLC
1 FEDERAL STREET, 38TH FLOOR, BOSTON, MASSACHUSETTS, 02110
CENTESSA BIOSCIENCES, INC
1 FEDERAL STREET, 38TH FLOOR, BOSTON, MASSACHUSETTS, 02110
PEARLRIVER BIO GMBH
1 FEDERAL STREET, 38TH FLOOR, BOSTON, MASSACHUSETTS, 02110
Z FACTOR LIMITED
1 FEDERAL STREET, 38TH FLOOR, BOSTON, MASSACHUSETTS, 02110
Covered Properties (56)
STAT Inhibitors and their Use in the Treatment and/or Prevention of Cancer
Application: 61/651,757 →
Salicylic Acid Derivatives, Pharmaceutically Acceptable Salt Thereof, Composition Thereof and Method of Use Thereof
Application: 16/451,883 →
Publication: US US20190382422A1
Alpha Substituted Stat Inhibitors and Compositions Thereof
Application: 62/985,685 →
Stat Inhibitory Compounds and Compositions
Application: 62/985,678 →
Squaryl and Heterocycle Containing Stat Inhibitors and Compositions
Application: 62/985,679 →
Stat Inhibitory Compounds and Compositions
Application: 63/074,905 →
Antigen Binding Molecules That Bind Light
Application: 62/621,346 →
Antigen Binding Molecules That Bind LIGHT
Application: 16/256,688 →
Publication: US US20190315876A1
Antigen Binding Molecules That Bind Light
Application: 16/480,367 →
Publication: US US20210284747A1
Anti C-Met Antibodies
Application: 16/980,015 →
Publication: US US20210009694A1
CD47 Binding Agents
Application: 17/041,100 →
Publication: US US20210179711A1
Method of Using Anti-CD47 Antibody Molecules
Application: 16/877,938 →
Publication: US US20200277375A1
Therapeutic Use of Bone Morphogenetic Proteins
Application: 16/415,006 →
Publication: US US20190359668A1
Medium- or Macro-Cyclic Benzyl-Substituted Heterocycle Derivatives and Related Uses
Application: 63/074,220 →
Bicyclic-Heterocycle Derivatives and Related Uses
Application: 63/074,216 →
Formulations of Lixivaptan for the Treatment of Polycystic Disease
Application: 16/620,144 →
Publication: US US20200147102A1
Formulations of Lixivaptan for the Treatment of Polycystic Kidney Disease
Application: 62/517,793 →
Formulations of Lixivaptan for the Treatment of Polycystic Disease
Application: 62/580,167 →
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
Application: 60/309,516 →
Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector function
Application: 60/441,307 →
Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector function
Application: 60/491,254 →
Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector function
Application: 60/495,142 →
Antigen Binding Molecules That Bind EGFR, Vectors Encoding Same, and Uses Thereof
Application: 15/965,143 →
Publication: US US20190106497A1
Chimeric EGFR antibody, vectors encoding same, and uses thereof
Application: 60/650,115 →
Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
Application: 60/836,371 →
Compounds and Their Use for the Treatment of ALPHA1-Antitrypsin Deficiency
Application: 17/345,928 →
Publication: US US20210332015A1
Modified Serpins for the Treatment of Bleeding Disorders
Patent: 9,982,035 →
Application: 15/103,420 →
Publication: US US20160311887A1
Modified Serpins for the Treatment of Bleeding Disorders
Application: 15/971,692 →
Publication: US US20180273610A1
Salicylic Acid Derivatives, Pharmaceutically Acceptable Salt Thereof, Composition Thereof and Method of Use Thereof
Patent: 9,650,399 →
Application: 14/550,293 →
Publication: US US20150158894A1
Salicylic Acid Derivatives, Pharmaceutically Acceptable Salt Thereof, Composition Thereof and Method of Use Thereof
Application: 15/475,108 →
Publication: US US20170267704A1
Sulfonamide Compounds and Their Use as STAT5 Inhibitors
Application: 15/315,324 →
Publication: US US20170101369A1
Anti-CD47 Antibody Molecules
Application: 16/543,884 →
Publication: US US20190375840A1
Therapeutic Use of Bone Morphogenetic Proteins
Application: 15/324,864 →
Publication: US US20170209540A1
Tricyclic Diazepine Vasopressin Antagonists and Oxytocin Antagonists
Patent: 5,516,774 →
Application: 08/254,822 →
Tricyclic Diazepine Vasopressin Antagonists and Oxytocin Antagonists
Patent: 5,624,923 →
Application: 08/468,737 →
Vasopressin Antagonist and Diuretic Combination
Patent: 6,420,358 →
Application: 09/669,461 →
Vasopressin Antagonist and Diuretic Combination
Patent: 6,656,931 →
Application: 10/162,451 →
Publication: US US20030069227A1
Vasopressin antagonist formulation and process
Patent: 6,352,718 →
Application: 09/668,883 →
Compositions for Delivery of Insoluble Agents
Patent: 8,877,746 →
Application: 13/391,440 →
Publication: US US20130079334A1
Pharmaceutical Carrier Formulation
Patent: 6,437,006 →
Application: 09/668,970 →
Glycosylation Engineering of Antibodies for Improving Antibody-Dependent Cellular Cytotoxicity
Patent: 6,602,684 →
Application: 09/294,584 →
Antibody Glycosylation Variants Having Increased Antibody-Dependent Cellular Cytotoxicity
Patent: 8,021,856 →
Application: 11/199,232 →
Publication: US US20080280322A9
Antibody Glycosylation Variants Having Increased Antibody-Dependent Cellular Cytotoxicity
Patent: 8,999,324 →
Application: 13/196,724 →
Publication: US US20110293609A1
Fusion Constructs and Use of Same to Produce Antibodies with Increased Fc Receptor Binding Affinity and Effector Function
Patent: 8,367,374 →
Application: 10/761,435 →
Publication: US US20040241817A1
Fusion Constructs and Use of Same to Produce Antibodies with Increased Fc Receptor Binding Affinity and Effector Function
Patent: 8,859,234 →
Application: 13/759,925 →
Publication: US US20140073005A1
Antigen Binding Molecules That Bind Egfr, Vectors Encoding Same, and Uses Thereof
Patent: 7,722,867 →
Application: 11/348,526 →
Publication: US US20080279858A9
Antigen Binding Molecules That Bind Egfr, Vectors Encoding Same, and Uses Thereof
Patent: 7,846,432 →
Application: 11/889,981 →
Publication: US US20090186019A1
Antigen Binding Molecules That Bind Egfr, Vectors Encoding Same, and Uses Thereof
Patent: 8,097,436 →
Application: 12/938,180 →
Publication: US US20110111461A1
Antigen Binding Molecules That Bind Egfr, Vectors Encoding Same, and Uses Thereof
Patent: 8,614,065 →
Application: 13/315,989 →
Publication: US US20120178106A1
Antigen Binding Molecules That Bind EGFR, Vectors Encoding Same, and Uses Thereof
Patent: 9,309,317 →
Application: 14/084,303 →
Publication: US US20140227253A1
Antigen Binding Molecules That Bind EGFR, Vectors Encoding Same, and Uses Thereof
Patent: 9,957,326 →
Application: 15/050,821 →
Publication: US US20160304614A1
Antigen Binding Molecules That Bind Egfr, Vectors Encoding Same, and Uses Thereof
Patent: 7,662,377 →
Application: 11/889,215 →
Publication: US US20080095770A1
Antigen Binding Molecules That Bind Egfr, Vectors Encoding Same, and Uses Thereof
Patent: 7,727,741 →
Application: 11/892,010 →
Publication: US US20090232817A9
Antigen Binding Molecules That Bind Egfr, Vectors Encoding Same, and Uses Thereof
Patent: 8,088,380 →
Application: 12/724,386 →
Publication: US US20100233080A1
Antigen Binding Molecules That Bind Egfr, Vectors Encoding Same, and Uses Thereof
Patent: 8,273,328 →
Application: 13/308,334 →
Publication: US US20120149033A1
Antigen Binding Molecules That Bind EGFR, Vectors Encoding Same, and Uses Thereof
Patent: 9,074,008 →
Application: 13/588,269 →
Publication: US US20130084284A1
Related Assignments (25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Aug 21, 2003
From: UMANA, PABLO; BRUENKER, PETER; FERRARA, CLAUDIA; SUTER, TOBIAS
To: GLYCART BIOTECHNOLGY AG
Reel/Frame 014537/0735 →
Assignment of Assignor's Interest Apr 20, 2004
From: UMANA, PABLO; BRUENKER, PETER; FERRARA, CLAUDIA; SUTER, TOBIAS
To: GLYCART BIOTECHNOLGY AG
Reel/Frame 014540/0542 →
Assignment of Assignor's Interest May 24, 2004
From: UMANA, PABLO; BRUENKER, PETER; FERRARA, CLAUDIA; SUTER, TOBIAS
To: GLYCART BIOTECHNOLOGY AG
Reel/Frame 015387/0258 →
Assignment of Assignor's Interest May 24, 2004
From: UMANA, PABLO; BRUENKER, PETER; FERRARA, CLAUDIA; SUTER, TOBIAS
To: GLYCART BIOTECHNOLOGY AG
Reel/Frame 015367/0657 →
Assignment of Assignor's Interest Apr 25, 2005
From: UMANA, PABLO; MOSSNER, EKKEHARD
To: GLYCART BIOTECHNOLOGY AG
Reel/Frame 015946/0231 →
Assignment of Assignor's Interest Jul 20, 2007
From: UMANA, PABLO; MOSSNER, EKKEHARD
To: GLYCART BIOTECHNOLOGY AG
Reel/Frame 019584/0424 →
Confirmatory License Jul 1, 2015
From: INDIANA UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 036042/0546 →
Assignment of Assignor's Interest Sep 20, 2016
From: HUNTINGTON, JAMES ANDREW; POLDERDIJK, STEPHANIE; BAGLIN, TREVOR
To: CAMBRIDGE ENTERPRISE LIMITED
Reel/Frame 039785/0296 →
Assignment of Assignor's Interest May 24, 2018
From: PELLEGRINI, LORENZO
To: PALLADIO BIOSCIENCES, INC.
Reel/Frame 045897/0751 →
Assignment of Assignor's Interest Jul 2, 2018
From: HUNTINGTON, JAMES ANDREW; POLDERDIJK, STÉPHANIE; BAGLIN, TREVOR
To: CAMBRIDGE ENTERPRISE LIMITED
Reel/Frame 046254/0403 →
Assignment of Assignor's Interest Jan 17, 2019
From: HOLMES, STEVE
To: CAPELLA BIOSCIENCE LTD.
Reel/Frame 048044/0697 →
Assignment of Assignor's Interest Apr 24, 2019
From: HOLMES, STEVE
To: CAPELLA BIOSCIENCE LTD.
Reel/Frame 048977/0906 →
Assignment of Assignor's Interest Dec 26, 2019
From: GUNNING, PATRICK THOMAS; HAFTCHENARY, SINA; PAGE, BRENT DAVID GEORGE
To: THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO
Reel/Frame 051366/0179 →
Assignment of Assignor's Interest Dec 26, 2019
From: WEISS, SAMUEL; LUCHMAN, HEMA ARTEE
To: UTI LIMITED PARTNERSHIP
Reel/Frame 051418/0169 →
Assignment of Assignor's Interest Dec 26, 2019
From: FISHEL, MELISSA L.
To: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
Reel/Frame 051366/0212 →
Assignment of Assignor's Interest Jan 22, 2020
From: FISHEL, MELISSA L.
To: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
Reel/Frame 051582/0400 →
Assignment of Assignor's Interest Jan 22, 2020
From: GUNNING, PATRICK THOMAS; HAFTCHENARY, SINA; PAGE, BRENT DAVID GEORGE
To: THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO
Reel/Frame 051582/0304 →
Assignment of Assignor's Interest Jan 22, 2020
From: WEISS, SAMUEL; LUCHMAN, HEMA ARTEE
To: UTI LIMITED PARTNERSHIP
Reel/Frame 051664/0915 →
Assignment of Assignor's Interest Jun 3, 2020
From: FLECK, ROMAN; PROUDFOOT, JOHN; OMEARA, JEFF; GUNNING, PATRICK THOMAS
To: JANPIX, LTD.
Reel/Frame 052824/0423 →
Assignment of Assignor's Interest Jun 3, 2020
From: FLECK, ROMAN; PROUDFOOT, JOHN; OMEARA, JEFF; GNANASEKARAN, KRISHNA KUMAR
To: JANPIX, LTD.
Reel/Frame 052824/0342 →
Assignment of Assignor's Interest Jun 22, 2020
From: FLECK, ROMAN; PROUDFOOT, JOHN; GNANASEKARAN, KRISHNA KUMAR; GUNNING, PATRICK THOMAS
To: JANPIX, LTD.
Reel/Frame 053000/0895 →
Assignment of Assignor's Interest Jun 30, 2020
From: FINLAY, WILLIAM JAMES JONATHAN
To: ULTRAHUMAN FOUR LIMITED
Reel/Frame 053089/0938 →
Assignment of Assignor's Interest Sep 23, 2020
From: FINLAY, WILLIAM JAMES JONATHAN
To: ULTRAHUMAN SIX LIMITED
Reel/Frame 053856/0961 →
Assignment of Assignor's Interest Sep 23, 2020
From: FLECK, ROMAN; PROUDFOOT, JOHN; OMEARA, JEFF; GUNNING, PATRICK THOMAS
To: JANPIX, LTD.
Reel/Frame 053854/0295 →
Assignment of Assignor's Interest Sep 29, 2020
From: FINLAY, WILLIAM JAMES JONATHAN
To: ULTRAHUMAN TWO LIMITED
Reel/Frame 053913/0676 →